Letybo at Rejuvenus Clinic.
You might have been hearing some buzz in Canada about a new neurotoxin approved in the medical aesthetic market, Letybo (also known as Letibotulinumtoxin A), from Croma Aesthetics Canada.
Letybo is the fifth neurotoxin approved in Canada, it is indicated for temporary improvement in the appearance of moderate to severe glabellar frown lines in adults. Neurotoxins such as Botox, Dysport, Nuceiva, Xeomin are the other toxins in Canada use in the aesthetic industry to reduce the appearance of fine lines and wrinkles. So let’s get to know this new product!
What should you know about Letybo?
Letybo [letibotulinumtoxinA] is a brand new (in the EU, UK and Canada at least) botulinum toxin type A being launched by from Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics.
This new toxin has received a Notice of Compliance from Health Canada for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity (frown lines between the eyebrows) in adult patients.
LetibotulinumtoxinA has been used in South Korea where it has been market leader for six consecutive years, , one of the world’s most dynamic aesthetic markets. With its recent approval in the EU, Letybo is now available in over 28 countries.
It was developed by Hugel in South Korea in the form Botulax. It is also marketed under the names Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot. Please note Botulax is not licensed in Canada (or FDA-approved) - if it is being used, it is either an illegal or fake product!
What is the research behind it?
The Canadian authorization of Letybo was based on the results of three identical randomized, controlled, multicenter phase 3 clinical trials involving 1,272 subjects with moderate-to-severe glabellar lines.
In each study, the primary endpoint was met; letibotulinumtoxinA (20 Units) was superior to placebo in reducing glabellar (frown) line severity at Week 4 based on a composite ≥2-point improvement in Facial Wrinkle Scale (FWS) score. It was also shown to be non-inferior to the leading competitor, Botox. It was deemed effective and safe.
What makes it different?
Letybo is Korea's top selling neurotoxin and a promising contender to botox and dysport.
South Korea is one of the world's leading pioneers in the beauty related industry, which encapsulates cosmetic procedures, skincare, fashion, hair treatments, and many more innovations.
They have extremely high standards and a well established reputation for premium aesthetics, so it's safe to say we are excited to be one of the first clinics to offer Canada's newest Neurotoxin.
Letybo provides a compelling new treatment option for physicians at Rejuvenus Clinic and their aesthetic patients. We are currently incorporating it into our aesthetic product offering. Contact Rejuvenus Clinic at 647.615.0223 to schedule a complementary consultation so we can answer any of your questions regarding your first Letybo appointment.